Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...

President-elect Donald Trump wants to buy the territory from Denmark, which says it’s not for sale. DealBook asked experts ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for ...

UK investment bank Peel Hunt suggests food inflation could near 4% by the end of 2025 as supermarkets react to cost pressures arising from Labour’s budget in October.

It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...